These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16022168)

  • 1. The use of weighted Z-tests in medical research.
    Lan KK; Soo Y; Siu C; Wang M
    J Biopharm Stat; 2005; 15(4):625-39. PubMed ID: 16022168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trimmed weighted Simes' test for two one-sided hypotheses with arbitrarily correlated test statistics.
    Brannath W; Bretz F; Maurer W; Sarkar S
    Biom J; 2009 Dec; 51(6):885-98. PubMed ID: 20014203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A type of sample size design in cancer clinical trials for response rate estimation.
    Liu J
    Contemp Clin Trials; 2011 Jan; 32(1):140-6. PubMed ID: 20965278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A composite design for transition from a preliminary to a full-scale study.
    Lachin JM; Younes N
    Stat Med; 2007 Nov; 26(27):5014-32. PubMed ID: 17577245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A note on two approaches of testing bridging evidence to a new region.
    Dong X; Guo Y; Tsong Y
    J Biopharm Stat; 2012 Sep; 22(5):966-76. PubMed ID: 22946943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-designing trial combined with classical group sequential monitoring.
    Yin G; Shen Y
    J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian sample size for diagnostic test studies in the absence of a gold standard: Comparing identifiable with non-identifiable models.
    Dendukuri N; Bélisle P; Joseph L
    Stat Med; 2010 Nov; 29(26):2688-97. PubMed ID: 20803558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A seamless phase II/III design with sample-size re-estimation.
    Bischoff W; Miller F
    J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical methods for bridging studies.
    Chow SC; Chiang C; Liu JP; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):903-15. PubMed ID: 22946939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [What to do if statistical power is low? A practical strategy for pre-post-designs].
    Müller J; Manz R; Hoyer J
    Psychother Psychosom Med Psychol; 2002; 52(9-10):408-16. PubMed ID: 12355348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size re-estimation in group-sequential response-adaptive clinical trials.
    Morgan CC
    Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Weighted estimation methods for multistage sampling survey data].
    Hou XY; Wei YY; Chen F
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jun; 30(6):633-6. PubMed ID: 19957636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian design and analysis for dose-response using informative prior information.
    Smith MK; Marshall S
    J Biopharm Stat; 2006; 16(5):695-709. PubMed ID: 17037266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of prior information for Bayesian evaluation of bridging studies.
    Hsiao CF; Hsu YY; Tsou HH; Liu JP
    J Biopharm Stat; 2007; 17(1):109-21. PubMed ID: 17219758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A practical comparison of group-sequential and adaptive designs.
    Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blinded sample size recalculation in multicentre trials with normally distributed outcome.
    Jensen K; Kieser M
    Biom J; 2010 Jun; 52(3):377-99. PubMed ID: 20394080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.